Carbidopa/oxitriptan

Carbidopa / oxitriptan

Carbidopa (top) and oxitriptan (bottom)
Combination of
Carbidopa	Aromatic L-amino acid decarboxylase inhibitor
Oxitriptan	Serotonin precursor
Clinical data
Other names	Carbidopa/5-hydroxytryptophan; Carbidopa/L-5-hydroxytryptophan; Carbidopa/5-HTP; Carbidopa/L-5-HTP; EVX-101
Routes of administration	By mouth
Identifiers
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}

Carbidopa/oxitriptan (developmental code name EVX-101), or carbidopa/5-hydroxytryptophan (carbidopa/5-HTP), is a combination of 5-hydroxytryptophan (oxitriptan), a serotonin precursor, and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase inhibitor, which is under development as an antidepressant for the treatment of depressive disorders. As of June 2020, it is in phase 1 clinical trials for this indication.

See also

• List of investigational antidepressants